Back to GetFilings.com




QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

FOR THE QUARTERLY PERIOD ENDED September 30, 2003

Commission file number 1-3433

THE DOW CHEMICAL COMPANY
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
      38-1285128
(I.R.S. Employer
Identification No.)

2030 DOW CENTER, MIDLAND, MICHIGAN 48674
(Address of principal executive offices) (Zip Code)

989-636-1000
(Registrant's telephone number, including area code)

Not applicable
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act) Yes ý    No o

Class
   
  Outstanding at September 30, 2003
Common Stock, par value $2.50 per share       920,534,758 shares




The Dow Chemical Company
Table of Contents

 
  PAGE
PART I—FINANCIAL INFORMATION    
 
Item 1. Financial Statements

 

3
   
Consolidated Statements of Income

 

3
   
Consolidated Balance Sheets

 

4
   
Consolidated Statements of Cash Flows

 

5
   
Consolidated Statements of Comprehensive Income

 

5
   
Notes to the Consolidated Financial Statements

 

6
 
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

19
   
Disclosure Regarding Forward-Looking Information

 

19
   
Results of Operations

 

19
   
Changes in Financial Condition

 

26
   
Other Matters

 

28
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

33
 
Item 4. Controls and Procedures

 

34

PART II—OTHER INFORMATION

 

 
 
Item 1. Legal Proceedings

 

35
 
Item 6. Exhibits and Reports on Form 8-K

 

35

SIGNATURE

 

36

EXHIBIT INDEX

 

37

2



PART I—FINANCIAL INFORMATION
ITEM 1.    Financial Statements

The Dow Chemical Company and Subsidiaries
Consolidated Statements of Income

 
  Three Months Ended
  Nine Months Ended
In millions, except per share amounts (Unaudited)

  Sept. 30,
2003

  Sept. 30,
2002

  Sept. 30,
2003

  Sept. 30,
2002

Net Sales   $ 7,977   $ 7,084   $ 24,300   $ 20,648
   
 
 
 
  Cost of sales     6,861     6,049     20,994     17,435
  Research and development expenses     247     262     730     784
  Selling, general and administrative expenses     334     389     1,043     1,185
  Amortization of intangibles     14     16     44     49
  Merger-related expenses and restructuring         32         55
  Equity in earnings of nonconsolidated affiliates     74     47     203     42
  Sundry income (expense)—net     69     18     115     1
  Interest income     22     13     60     43
  Interest expense and amortization of debt discount     204     194     626     571
   
 
 
 
Income before Income Taxes and Minority Interests     482     220     1,241     655
   
 
 
 
  Provision for income taxes     127     67     360     202
  Minority interests' share in income     23     25     71     49
   
 
 
 
Income before Cumulative Effect of Changes in Accounting
        Principles
    332     128     810     404
   
 
 
 
  Cumulative effect of changes in accounting principles             (9 )   67
   
 
 
 
Net Income Available for Common Stockholders   $ 332   $ 128   $ 801   $ 471
   
 
 
 
Share Data                        
  Earnings before cumulative effect of changes in accounting
        principles per common share—basic
  $ 0.36   $ 0.14   $ 0.88   $ 0.44
  Earnings per common share—basic   $ 0.36   $ 0.14   $ 0.87   $ 0.52
  Earnings before cumulative effect of changes in accounting
        principles per common share—diluted
  $ 0.36   $ 0.14   $ 0.88   $ 0.44
  Earnings per common share—diluted   $ 0.36   $ 0.14   $ 0.87   $ 0.51
  Common stock dividends declared per share of common stock   $ 0.335   $ 0.335   $ 1.005   $ 1.005
  Weighted-average common shares outstanding—basic     919.8     911.7     917.3     909.9
  Weighted-average common shares outstanding—diluted     926.5     917.9     922.9     917.3
   
 
 
 
Depreciation   $ 434   $ 417   $ 1,293   $ 1,207
   
 
 
 
Capital Expenditures   $ 256   $ 398   $ 751   $ 1,086
   
 
 
 

See Notes to the Consolidated Financial Statements.

3


The Dow Chemical Company and Subsidiaries
Consolidated Balance Sheets

In millions (Unaudited)

  Sept. 30,
2003

  Dec. 31,
2002

 
Assets              
Current Assets              
  Cash and cash equivalents   $ 2,566   $ 1,484  
  Marketable securities and interest-bearing deposits     47     89  
  Accounts and notes receivable:              
    Trade (net of allowance for doubtful receivables—2003: $124; 2002: $127)     3,144     3,116  
    Other     2,184     2,369  
  Inventories     4,167     4,208  
  Deferred income tax assets—current     133     109  
   
 
 
  Total current assets     12,241     11,375  
   
 
 
Investments              
  Investment in nonconsolidated affiliates     1,800     1,565  
  Other investments     1,924     1,689  
  Noncurrent receivables     308     577  
   
 
 
  Total investments     4,032     3,831  
   
 
 
Property              
  Property     39,307     37,934  
  Less accumulated depreciation     25,797     24,137  
   
 
 
  Net property     13,510     13,797  
   
 
 
Other Assets              
  Goodwill     3,226     3,189  
  Other intangible assets (net of accumulated amortization—2003: $380; 2002: $349)     590     613  
  Deferred income tax assets—noncurrent     3,850     3,776  
  Asbestos-related insurance receivables—noncurrent     1,300     1,489  
  Deferred charges and other assets     1,556     1,492  
   
 
 
  Total other assets     10,522     10,559  
   
 
 
Total Assets   $ 40,305   $ 39,562  
   
 
 
Liabilities and Stockholders' Equity              
Current Liabilities              
  Notes payable   $ 371   $ 580  
  Long-term debt due within one year     1,086     797  
  Accounts payable:              
    Trade     2,601     2,834  
    Other     1,987     1,789  
  Income taxes payable     217     202  
  Deferred income tax liabilities—current     32     30  
  Dividends payable     308     326  
  Accrued and other current liabilities     2,551     2,298  
   
 
 
  Total current liabilities     9,153     8,856  
   
 
 
Long-Term Debt     11,695     11,659  
   
 
 
Other Noncurrent Liabilities              
  Deferred income tax liabilities—noncurrent     1,117     994  
  Pension and other postretirement benefits—noncurrent     3,834     3,775  
  Asbestos-related liabilities—noncurrent     1,923     2,072  
  Other noncurrent obligations     3,255     3,214  
   
 
 
  Total other noncurrent liabilities     10,129     10,055  
   
 
 
Minority Interest in Subsidiaries     368     366  
   
 
 
Preferred Securities of Subsidiaries     1,000     1,000  
   
 
 
Stockholders' Equity              
  Common stock     2,453     2,453  
  Additional paid-in capital     1      
  Unearned ESOP shares     (52 )   (61 )
  Retained earnings     9,376     9,520  
  Accumulated other comprehensive loss     (1,857 )   (2,097 )
  Treasury stock at cost     (1,961 )   (2,189 )
   
 
 
  Net stockholders' equity     7,960     7,626  
   
 
 
Total Liabilities and Stockholders' Equity   $ 40,305   $ 39,562  
   
 
 

See Notes to the Consolidated Financial Statements.

4


The Dow Chemical Company and Subsidiaries
Consolidated Statements of Cash Flows

 
   
  Nine Months Ended
 
In millions (Unaudited)

  Sept. 30,
2003

  Sept. 30,
2002

 
Operating Activities   Income before cumulative effect of changes in accounting
    principles
  $ 810   $ 404  
    Adjustments to reconcile net income to net cash provided
    by operating activities:
             
        Depreciation and amortization     1,401     1,305  
        Provision for deferred income tax     122     15  
        Earnings/losses of nonconsolidated affiliates less than
        (in excess of) dividends received
    (88 )   27  
        Minority interests' share in income     71     49  
        Net (gain) loss on sales of consolidated companies     3     (4 )
        Net gain on sales of property and businesses     (93 )   (11 )
        Other net gain     (17 )   (28 )
        Net gain on sales of nonconsolidated affiliates     (21 )    
        Tax benefit—nonqualified stock option exercises     23     18  
    Changes in assets and liabilities that provided (used) cash:              
        Accounts and notes receivable     (288 )   (505 )
        Inventories     (22 )   (49 )
        Accounts payable     (48 )   100  
        Noncurrent receivables     269     136  
        Other assets and liabilities     608     (114 )
       
 
 
    Cash provided by operating activities     2,730     1,343  
       
 
 
Investing Activities   Capital expenditures     (751 )   (1,086 )
    Proceeds from sales of property and businesses     202     52  
    Acquisitions of businesses, net of cash received     (8 )    
    Investments in consolidated companies     (69 )    
    Proceeds from sales of consolidated companies         39  
    Investments in nonconsolidated affiliates     (70 )   (74 )
    Proceeds from sales of nonconsolidated affiliates     51      
    Purchases of investments     (1,283 )   (1,362 )
    Proceeds from sales and maturities of investments     1,136     1,338  
       
 
 
    Cash used in investing activities     (792 )   (1,093 )
       
 
 
Financing Activities   Changes in short-term notes payable     (195 )   (274 )
    Payments on long-term debt     (797 )   (424 )
    Proceeds from issuance of long-term debt     901     1,596  
    Purchases of treasury stock     (5 )   (3 )
    Proceeds from sales of common stock     138     118  
    Distributions to minority interests     (53 )   (67 )
    Dividends paid to stockholders     (920 )   (912 )
       
 
 
    Cash provided by (used in) financing activities     (931 )   34  
       
 
 
Effect of Exchange Rate Changes on Cash     75     (4 )
       
 
 
Summary   Increase in cash and cash equivalents     1,082     280  
    Cash and cash equivalents at beginning of year     1,484     220  
       
 
 
    Cash and cash equivalents at end of period   $ 2,566   $ 500  
       
 
 

See Notes to the Consolidated Financial Statements.

The Dow Chemical Company and Subsidiaries
Consolidated Statements of Comprehensive Income

 
  Three Months Ended
  Nine Months Ended
 
In millions (Unaudited)

  Sept. 30,
2003

  Sept. 30,
2002

  Sept. 30,
2003

  Sept. 30,
2002

 
Net Income Available for Common Stockholders   $ 332   $ 128   $ 801   $ 471  
Other Comprehensive Income (Loss), Net of Tax                          
  Net unrealized gains (losses) on investments     3     (41 )   35     (64 )
  Translation adjustments     51     (47 )   236     137  
  Minimum pension liability adjustments             (3 )    
  Net losses on cash flow hedging derivative instruments     (30 )   (23 )   (28 )   (19 )
   
 
 
 
 
  Total other comprehensive income (loss)     24     (111 )   240     54  
   
 
 
 
 
Comprehensive Income   $ 356   $ 17   $ 1,041   $ 525  
   
 
 
 
 

See Notes to the Consolidated Financial Statements.

5



The Dow Chemical Company and Subsidiaries
Notes to the Consolidated Financial Statements

(Unaudited)

NOTE A—CONSOLIDATED FINANCIAL STATEMENTS

        The unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) which, in the opinion of management, are considered necessary for a fair presentation of the results for the periods covered. Certain reclassifications of prior year amounts have been made to conform to current year presentation. These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2002. Except as otherwise indicated by the context, the terms "Company" or "Dow" as used herein mean The Dow Chemical Company and its consolidated subsidiaries.

NOTE B—ACCOUNTING CHANGES

        In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations," which replaced Accounting Principles Board ("APB") Opinion No. 16, "Business Combinations." Under SFAS No. 141, all business combinations initiated after June 30, 2001 are accounted for using the purchase method. As required by SFAS No. 141, negative goodwill of $89 million associated with the acquisition of Buna Sow Leuna Olefinverbund ("BSL") in 1997 was written off and included in "Cumulative effect of changes in accounting principles" in the first quarter of 2002. The application of SFAS No. 141 did not result in the reclassification of any amounts previously recorded as goodwill or other intangible assets.

        In June 2001, the FASB issued SFAS No. 142, "Goodwill and Other Intangible Assets," which replaced APB Opinion No. 17, "Intangible Assets," and established new accounting and reporting requirements for goodwill and other intangible assets, effective for fiscal years beginning after December 15, 2001. Under this statement, goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but are subject to impairment testing. Impairment testing was required at adoption and at least annually thereafter. On an ongoing basis (absent any impairment indicators), Dow performs impairment tests during the fourth quarter of each year, in conjunction with the Company's annual budgeting process. Effective January 1, 2002, Dow ceased all amortization of goodwill, which is its only intangible asset with an indefinite useful life, and tested recorded goodwill for impairment by comparing the fair value of each reporting unit, determined using a discounted cash flow method, with its carrying value.

        As a result of the Company's impairment testing, goodwill impairment losses totaling $22 million were recorded in the first quarter of 2002 and included in "Cumulative effect of changes in accounting principles." Summaries of the impairment losses are as follows:

        As required by SFAS No. 142, the Company also reassessed the useful lives and the classification of its identifiable intangible assets and determined them to be appropriate. See Note E for disclosures related to goodwill and other intangible assets.

        In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations," which requires an entity to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the related long-lived asset. The liability is adjusted to its present value each period and the asset is depreciated over its useful life. A gain or loss may be incurred upon settlement of the liability. SFAS No. 143 was effective for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 on January 1, 2003 resulted in the recognition of an asset retirement obligation of $45 million and a charge of $9 million (net of tax of $5 million), which was included in "Cumulative effect of changes in accounting principles." See Note H for disclosures related to asset retirement obligations.

        In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities," which nullifies Emerging Issues Task Force ("EITF") Issue 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity." This statement, which was effective for exit or disposal activities initiated after December 31, 2002, will change the measurement and timing of costs associated with exit and disposal activities undertaken by the Company in the future.

6


        In the first quarter of 2003, Dow adopted the fair value provisions of SFAS No. 123, "Accounting for Stock-Based Compensation," for new grants of equity instruments (which include stock options, deferred stock grants, and subscriptions to purchase shares under the Company's Employees' Stock Purchase Plan) to employees. Dow expects the incremental after-tax expense associated with awards of stock options to be approximately $0.02 per share in 2003, growing to approximately $0.06 per share in 2005. These estimates were based on the terms of Dow's stock option plans and current assumptions for stock option grants and valuation, which may change when stock options are granted in the future. See Note I for disclosures required by SFAS No. 148, "Accounting for Stock-Based Compensation—Transition and Disclosure."

        In November 2002, the FASB issued FASB Interpretation ("FIN") No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN No. 45 clarifies the requirements of SFAS No. 5, "Accounting for Contingencies," relating to the guarantor's accounting for and disclosures of certain guarantees issued. The initial recognition and measurement provisions of the interpretation are applicable on a prospective basis to guarantees issued or modified after December 31, 2002, irrespective of the guarantor's fiscal year-end. The disclosure requirements of the interpretation were effective for financial statements of interim or annual periods ending after December 15, 2002. The Company's disclosures related to guarantees can be found in Note F.

        In January 2003, the FASB issued FIN No. 46, "Consolidation of Variable Interest Entities." FIN No. 46 clarifies the application of Accounting Research Bulletin No. 51, "Consolidated Financial Statements," to certain entities in which equity investors do not have the characteristics of a controlling financial interest or in which equity investors do not bear the residual economic risks. The interpretation was immediately applicable to variable interest entities ("VIEs") created after January 31, 2003, and to VIEs in which an enterprise obtains an interest after that date. As originally issued, it applied in the fiscal year or interim period beginning after June 15, 2003, to VIEs in which an enterprise holds a variable interest that was acquired before February 1, 2003. In October 2003, the FASB issued FASB Staff Position No. 46-6, which defers the effective date for FIN No. 46 to the first interim or annual period ending after December 15, 2003 for VIEs created before February 1, 2003. See Note G for disclosures regarding the Company's VIEs, and the expected impact of adoption in the fourth quarter of 2003.

        In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity." SFAS No. 150 requires the classification of certain financial instruments that embody obligations for the issuer as liabilities (or assets in some circumstances). SFAS No. 150 was effective for financial instruments entered into or modified after May 31, 2003, and otherwise was effective at the beginning of the first interim period beginning after June 15, 2003. The Company evaluated the preferred securities previously issued by two consolidated subsidiaries and concluded that the $500 million of preferred securities issued by Hobbes Capital S.A. is outside of the scope of the standard and will continue to be classified as "Preferred Securities of Subsidiaries." The $500 million of preferred partnership units issued by Tornado Finance V.O.F. ("Tornado") is within the scope of the standard and was classified as a liability of the Company upon adoption of SFAS No. 150 on July 1, 2003. The rights of the holders of Tornado's preferred partnership units were subsequently modified to eliminate the unconditional mandatory redemption feature; therefore, the preferred partnership units were classified as "Preferred Securities of Subsidiaries" in the consolidated balance sheet at September 30, 2003. See Note P to the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2002 for additional information.

NOTE C—MERGER-RELATED EXPENSES AND RESTRUCTURING

Merger-Related Expenses and Restructuring

        On February 6, 2001, the merger of Union Carbide Corporation ("Union Carbide") with a subsidiary of The Dow Chemical Company was completed, and Union Carbide became a wholly owned subsidiary of Dow. Following the completion of the Union Carbide merger, Dow's management made certain decisions relative to employment levels, duplicate assets and facilities and excess capacity resulting from the merger. These decisions resulted in a pretax special charge in the first quarter of 2001 of $1.4 billion. The planned merger-related program was substantially completed in the third quarter of 2002. Complete disclosures relative to the program and the activity in the merger-related special charge reserve can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2002.

        In conjunction with this program, merger-related expenses of $50 million (including $21 million of severance), exclusively related to the merger, were recorded in the first nine months of 2002. In the third quarter of 2002, the Company also recorded severance of $5 million related to a workforce reduction program at Dow AgroSciences.

        During the fourth quarter of 2002, an additional charge of $34 million was recorded for merger-related severance. Under this revised severance program, $62 million was paid to 746 former employees in the first quarter of 2003.

7


Other Restructuring

        In late 2002, immediately following the appointment of a new President and CEO, management began a series of studies to determine potential actions relative to under-performing assets and employment levels. Prior to the end of 2002, certain studies were completed and management made